POLX Stock Overview
Operates as a drug-device manufacturer and service provider for noble gas polariser devices in Canada, the United Kingdom, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Polarean Imaging plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.013 |
| 52 Week High | UK£0.085 |
| 52 Week Low | UK£0.01 |
| Beta | 0.27 |
| 1 Month Change | -16.13% |
| 3 Month Change | -14.75% |
| 1 Year Change | -79.20% |
| 3 Year Change | -97.70% |
| 5 Year Change | -94.09% |
| Change since IPO | -91.88% |
Recent News & Updates
Recent updates
Polarean Imaging (LON:POLX) Is In A Good Position To Deliver On Growth Plans
Oct 16
Here's Why Polarean Imaging (LON:POLX) Must Use Its Cash Wisely
Jan 09Is Polarean Imaging (LON:POLX) In A Good Position To Invest In Growth?
Sep 11Is Polarean Imaging (LON:POLX) In A Good Position To Invest In Growth?
Feb 09We're Keeping An Eye On Polarean Imaging's (LON:POLX) Cash Burn Rate
Oct 09Polarean Imaging (LON:POLX) Is In A Good Position To Deliver On Growth Plans
Dec 15We Think Shareholders Will Probably Be Generous With Polarean Imaging plc's (LON:POLX) CEO Compensation
Jul 07Here's Why We're Watching Polarean Imaging's (LON:POLX) Cash Burn Situation
Jun 07Insider Buying: The Polarean Imaging plc (LON:POLX) Independent Chairman Just Bought 6.6% More Shares
Mar 18Polarean Imaging (LON:POLX) Is In A Good Position To Deliver On Growth Plans
Mar 09Polarean Imaging (LON:POLX) Shareholders Have Enjoyed An Impressive 135% Share Price Gain
Feb 01
Should You Take Comfort From Insider Transactions At Polarean Imaging plc (LON:POLX)?
Dec 28What Type Of Shareholders Own The Most Number of Polarean Imaging plc (LON:POLX) Shares?
Nov 30Shareholder Returns
| POLX | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.5% | -0.6% |
| 1Y | -79.2% | -9.6% | 2.7% |
Return vs Industry: POLX underperformed the UK Medical Equipment industry which returned -9.7% over the past year.
Return vs Market: POLX underperformed the UK Market which returned 3.1% over the past year.
Price Volatility
| POLX volatility | |
|---|---|
| POLX Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: POLX has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: POLX's weekly volatility has decreased from 15% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 29 | Chris Von Jako | polarean.com |
Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas polariser devices in Canada, the United Kingdom, and the United States. It engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. The company also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; and measurement station, chest coil, and dose delivery inhalation bags.
Polarean Imaging plc Fundamentals Summary
| POLX fundamental statistics | |
|---|---|
| Market cap | UK£15.69m |
| Earnings (TTM) | -UK£6.81m |
| Revenue (TTM) | UK£1.49m |
10.5x
P/S Ratio-2.3x
P/E RatioIs POLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| POLX income statement (TTM) | |
|---|---|
| Revenue | US$1.87m |
| Cost of Revenue | US$1.03m |
| Gross Profit | US$836.63k |
| Other Expenses | US$9.38m |
| Earnings | -US$8.55m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0071 |
| Gross Margin | 44.78% |
| Net Profit Margin | -457.39% |
| Debt/Equity Ratio | 0% |
How did POLX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 11:25 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Polarean Imaging plc is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colin Smith | Capital Access Group |
| Christian Glennie | Stifel, Equities Research |
| null null | Stifel, Equities Research |